Defining Continuous Glucose Monitor Time in Range in a Large, Community-Based Cohort Without Diabetes
Authors' conclusion
Our results contribute to the understanding of the physiological CGM range in more than 1000 participants without diabetes. These results are also important for clinicians to reference as CGM sensors become more widely accessible to people without known diabetes.
Study context
- Population
- Community-dwelling adults of the Framingham Heart Study who wore a blinded Dexcom G6 Pro continuous glucose monitor (CGM) for ≥7 complete days; normoglycemic: mean age 58.5 years, 64.5% women, 93.3% non-Hispanic White
- Participants
- 560 / 463 / 152
- Exposure
- CGM metrics across glycemic status: normoglycemia, prediabetes, diabetes
- Normoglycemian = 560
- Prediabetesn = 463
- Diabetesn = 152
- Outcome
- CGM metrics incl. mean glucose and time spent in glucose ranges
Methodological detailswithin the Framingham Heart Study prospective cohort, blinded CGM (Dexcom G6 Pro) ≥7 complete days
- Within the Framingham Heart Study prospective cohort
- Blinded CGM (Dexcom G6 Pro) ≥7 complete days
Main finding
As reported in the abstract
CGM time in 70 to 140 mg/dL range
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| CGM time >180 mg/dL, normoglycemic participantsOn average | Normoglycemic mean 1.2% time · time per day more than 15 minutes/day |
| CGM time >140 mg/dL, normoglycemic participants | Normoglycemic 12.1% time · time per day ≈3 hours/day |
Original publication
Defining Continuous Glucose Monitor Time in Range in a Large, Community-Based Cohort Without Diabetes. J Clin Endocrinol Metab. Published 11 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →